Reply: ‘Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab’

por Gualberto, A, Hixon, M L, Pollak, M
Publicado 2011

Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab

por Gualberto, A, Hixon, M L, Karp, D D, Li, D, Green, S, Dolled-Filhart, M, Paz-Ares, L G, Novello, S, Blakely, J, Langer, C J, Pollak, M N
Publicado 2011

Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab

por Gualberto, A, Hixon, M L, Karp, D D, Li, D, Green, S, Dolled-Filhart, M, Paz-Ares, L G, Novello, S, Blakely, J, Langer, C J, Pollak, M N
Publicado 2012